These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1665417)

  • 41. The antimicrobial activity of sparfloxacin, a new quinolone.
    Paradelis AG; Delidou K; Grigoriadou A; Salpigides G; Pangalis A
    Drugs; 1995; 49 Suppl 2():238-9. PubMed ID: 8549316
    [No Abstract]   [Full Text] [Related]  

  • 42. Temafloxacin does not potentiate the anticoagulant effect of warfarin in healthy subjects.
    Millar E; Coles S; Wyld P; Nimmo W
    Clin Pharmacokinet; 1992; 22 Suppl 1():102-6. PubMed ID: 1319866
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro activity of MF 5137, a new potent 6-aminoquinolone.
    Wise R; Pagella PG; Cecchetti V; Fravolini A; Tabarrini O
    Drugs; 1995; 49 Suppl 2():272-3. PubMed ID: 8549329
    [No Abstract]   [Full Text] [Related]  

  • 44. A review of the pharmacokinetic profile of temafloxacin.
    Dudley MN
    J Antimicrob Chemother; 1991 Dec; 28 Suppl C():55-64. PubMed ID: 1664830
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oral temafloxacin approved for U.S. market.
    Clin Pharm; 1992 May; 11(5):381. PubMed ID: 1316251
    [No Abstract]   [Full Text] [Related]  

  • 46. Pharmacokinetics and biliary elimination of temafloxacin in pigs.
    Jehl F; Bresler L; Koechlin C; Merle-Melet M; Didelot JP; Hazebroucq J
    J Antimicrob Chemother; 1992 Aug; 30(2):189-96. PubMed ID: 1328135
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Time-kill studies of the activity of temafloxacin against four strains of Bacteroides.
    Brown WJ; Moosavi S
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S355-6. PubMed ID: 8391863
    [No Abstract]   [Full Text] [Related]  

  • 48. Comparative in vitro activity of BAY Y 3118 against selected species.
    Verbist L; Verhaegen J
    Drugs; 1995; 49 Suppl 2():264-5. PubMed ID: 8549326
    [No Abstract]   [Full Text] [Related]  

  • 49. Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria.
    Cormican MG; Jones RN
    J Antimicrob Chemother; 1995 Aug; 36(2):431-4. PubMed ID: 8522474
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin.
    Nye K; Shi YG; Andrews JM; Ashby JP; Wise R
    J Antimicrob Chemother; 1989 Sep; 24(3):415-24. PubMed ID: 2808194
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The in-vitro activity of tosufloxacin, a new fluorinated quinolone, compared with that of ciprofloxacin and temafloxacin.
    King A; Bethune L; Phillips I
    J Antimicrob Chemother; 1991 Nov; 28(5):719-25. PubMed ID: 1663930
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Initial clinical experience with clinafloxacin in the treatment of serious infections.
    Tack KJ; McGuire NM; Eiseman IA
    Drugs; 1995; 49 Suppl 2():488-91. PubMed ID: 8549411
    [No Abstract]   [Full Text] [Related]  

  • 53. In-vitro activity of OPC-17116 against more than 6000 consecutive clinical isolates: a multicentre international study.
    Marco F; Jones RN; Hoban DJ; Pignatari AC; Yamane N; Frei R
    J Antimicrob Chemother; 1994 Mar; 33(3):647-54. PubMed ID: 8040130
    [No Abstract]   [Full Text] [Related]  

  • 54. The in-vitro activity of a new highly active quinolone, DU-6859a.
    Jolley A; Andrews JM; Brenwald N; Wise R
    J Antimicrob Chemother; 1993 Nov; 32(5):757-63. PubMed ID: 8125840
    [No Abstract]   [Full Text] [Related]  

  • 55. In vitro activity of temafloxacin against gram-positive cocci including methicillin-resistant Staphylococcus aureus.
    Fuchs PC
    Am J Med; 1991 Dec; 91(6A):15S-18S. PubMed ID: 1662886
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Concentration of enrofloxacin in equine tissues after long-term oral administration.
    Giguère S; Bélanger M
    J Vet Pharmacol Ther; 1997 Oct; 20(5):402-4. PubMed ID: 9350262
    [No Abstract]   [Full Text] [Related]  

  • 57. Topical fluoroquinolones: antimicrobial activity and in vitro corneal epithelial toxicity.
    Cutarelli PE; Lass JH; Lazarus HM; Putman SC; Jacobs MR
    Curr Eye Res; 1991 Jun; 10(6):557-63. PubMed ID: 1893771
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro activity of lomefloxacin, a new difluorinated quinolone, against urinary bacterial isolates: comparison with enoxacin and ofloxacin.
    Azadian BS; Talboys CA; Roberts AP
    J Chemother; 1989 Jul; 1(4 Suppl):176-7. PubMed ID: 16312357
    [No Abstract]   [Full Text] [Related]  

  • 59. Temafloxacin: in vitro comparison with five other antibacterial agents.
    Digranes A; Hardardottir H; Bottolfsen KL
    Chemotherapy; 1991; 37(2):98-105. PubMed ID: 2032475
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Temafloxacin: a safe antibiotic for the elderly, patients with comorbidities, and other special populations.
    Pernet AG
    Am J Med; 1991 Dec; 91(6A):162S-165S. PubMed ID: 1662888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.